• Moore RA. Inflammation of the prostate gland. J Urol. 38:173, 1937
• Mortensen A, Skibsted L. Real time detection of reactions between radicals of lycopene and tocopherol homologues Free Radic Res 27(2):229-234, 1997
• Morris J, Pramanik R, Zhang X. Selenium-or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity. Cáncer Lett. 239(1):111-122, 28 Jul 2006
• Mostofi F et al. Prostatic intraepithelial neoplasía (PIN): morphological clinical significance. Prostate Suppl. 4:71-77, 1992
• Moyad M et al. Complementary Medicine for prostate cáncer:Effects of Soy and fat consumption. Rev Urol 3 Suppl 2:S20-30, 2001
• Moyad M. Selenium and vitamin E supplements for prostate cáncer: evidence or embellishment. Urology 2002 April 59:9-19, 2002
• Moyad M, Brumfield S, Pienta K. Vitamin E, alpha and gamma tocopherol and prostate cáncer. Sem Urol Oncol 17:85-90,1999
• Moyad M, Pienta K. Complementary Medicine for prostatic diseases: a primer for clinicians Urology 59(4A) Suppl April 2002
• Moyad M, Marks L, Thompson I. Complementary & Alternative Medicine for the Urologist: from A to Z. What do I Tell my patients. Postgraduate Course AUA 97th Annual Meeting Orlando 2002
• Moyad M. Results and Lessons from Clinical Trials using dietary supplements for cáncer: Direct and Indirect Investigations. Seminars in Urologic Oncology 19(4) 232-246, Nov 2001
• Moyad M. The ABC of Nutrition and Supplementats for Prostate Cáncer. Sleeping Bear Press 2000
• Moyad M. Complementary Medicine in Urology. The Urologic Clinics of North America 29(1):1-266. Feb 2002
• Moyad M, Carroll P. Lifestyle recommendations to prevent prostate cáncer, part II: Time to redirect our attention? Urol Clin N Am 31(2):301-311, May 2004.
• Moyad M. Lifestyle/Dietary supplement partial androgen supression and /or estrogen manipulation a novel PSA reducer and preventive/treatment option for prostate cáncer? Urol Clin North Am 29(1) 115-124, 2002
• Moyad M. Preventive Medicine and Men´s Health. Urol Clin North Am. 31(2):195-387, May 2004.
• Mukherjee P, Sotnikov A, Mangian H et al Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cáncer Inst. 17;91(6):512-523, Mar 1999
• Mulligan A, Welch A, McTaggart A et al. Intakes and sources of soya foods and isoflavones in a UK population cohort study (EPIC-Norfolk). Eur J Clin Nutr 61(2):248-254, Feb 2007
• Mydlo J, Gerstein M, Harris C et al. Immune function, mitogenicity, and angiogenic growth factor concentrations in lean and obese rodent sera: implications in obesity-related prostate tumor biology. Prostate Cáncer and Prostatic Diseases December 6(4):286-289, 2003
• Myers C Jr, Sgarlat S et al. Eating Your Way to Better Health-The Prostate Forum Nutrition Guide 2000. Rivanna Health Pubns Inc
• Myers C, Ghosh J. Molecular Targets for Chemoprevention of Prostate Cáncer. Lipooxygenase inhibition in prostate cáncer. Eur Urol 35(5-6):395-398,1999
• Myers CE Jr, Sgarlat Steck S, Sgarlat Myers R. Eating Your Way to Better Health-The Prostate Forum Nutrition Guide 2000. Rivanna Health Pubns Inc
• Myers C, Kofi A et al. Proapoptotic anti-inflamatory drugs. Urology 57 (suppl 4A):73-76:2001
• Nagata C. Ecological study of the association between soy product intake and mortality from cáncer and heart disease in Japan Int J Epidemiol29(5):832-836, 2000
• Nagata C, Inaba S, Kawakami N. Inverse association of soy product intake with serum androgen and estrogen concentration in Japanese men. Nutr Cáncer 36(1):14-18,2000
• Nagle R.New relationships between prostatic intraepithelial neoplasía and prostatic carcinoma. J Cell Bioch Suppl 16H: 26-9, 1992.
• Naik H, Lehr J, Pienta K. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cáncer. Anticáncer Res. 14(6B):2617-2619, 1994
• Nakai Y, Hicks J, Nelson W, De Marzo A. The dietary charred meat carcinogen 2-amino-1-methyl-6-phenylimidazo (4,5-B) pyridine (Phip) Acts as an initiator and tumor promoter in the rat ventral prostate. J Urol 175(4) Supplm:266 April 2006
• Nam R, Fleshner N, Rakovitch E. Prevalence and patterns use of complementary therapies among prostate cáncer patients: an epidemiological analysis. J Urol 161: 1521-1524, 1999
• NCI, DCPC Chemoprevention Branchan Agent Development Committee Clinical development plan: Tea extracts green tea polyphenols epigallocatechin gallate. J Cellular Biochemistry 26S:236-257, 1996
• National Institutes of Health. The National Kidney and Urologic Diseases Advisory Board 1990 long-range plan. Bethesda (MD): U.S. Department of Health and Human Services, Public Health Service, NIH 1990
• Nelson W, Wilding G. Prostate cáncer prevention agent development criteria and pipeline for candidate chemoprevention agents. Urology 57(4A) 56-63, April 2001.
• Nelson W.Prostate cáncer prevention.This review focuses on prostate cáncer prevention in the context of new mechanistic insights into human prostatic carcinogenesis. Current Opinion in Urology. 17(3):157-167, May 2007.
• Nelson P, Brawer M. Chemoprevention of Prostate Carcinoma. Urol Inter 4(4),7-9. Oct 1997.
• Nelson N. Is chemoprevention overrated or underfunded?. J Nat Cáncer Inst 88:947-949, 1996
• Nelson P, Gleason T, Brawer M. Chemoprevention for prostatic intraepithelial neoplasía. European Urology 30(2): 269-278,1996.
• Nelson M et al. Selenium and prostate cáncer prevention. Seminars in Urology Oncology. 17(2): 91-96 May 1999,
• Nelson W, De Marzo A, De Weese T. The molecular pathogenesis of prostate cáncer: implications for prostate cáncer prevention. Urology 57(4A)39-45,April 2001.
• Nelson W, De Weese T, DeMarzo A et al. The diet, prostate inflammation, and the development of prostate cáncer. Cáncer Metastasís Rev. 21(1):3-16, 2002
• Nelson W, De Marzo A, Isaacs W. Prostate Cáncer. Nelson W, De Marzo A,Isaacs W.New Eng J Med 349:366-381, 2003. New Eng J Med 349:366-381, 2003
• Nelson W et al. The role of inflammation in the pathogenesis of prostate cáncer. J Urol 172(5) part 2 of 2: S6-S12, Nov 2004
• Nelson WG, De Marzo AM, Isaacs WB. Prostate cáncer. New Eng J Med 349:366-381, 2003
• Ni H, Simile C, Hardy AM: Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. Med Care 40 (4): 353-358, 2002
• Nickel J et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasía. Br J Urol. 84:976-981, 1999
• Nomura A et al. Serum selenium and subsequent risk of prostate cáncer. Cáncer Epidemiol Biomarkers Prev 9:883-887,2000
• Nomura A, Kolonel L. Prostate cáncer. A current Perspective. Am J Epidemiol 13:200-227,1991
• Nomura A, Heilbrun L, Morris J, et al. Serum selenium and the risk of cáncer, by specific sites: case-control analysis of prospective data. Journal of the National Cáncer Institute 79(1): 103-108, 1987.
• Norrish A et al. Non-steroidal anti-inflammatory drugs and prostate cáncer progression. Int J Cáncer 77:511-515, Aug 1998
• Norrish A, Skeaf C, Arribas G. Prostate cáncer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cáncer 81(7):1238-1242, 1999
• Nutrición y Cáncer de Próstata. Centaurus 4(2):16-18,2002
• Odunjo E, Elebute E. Chronic prostatitis in benign prostatic hyperplasía. Br J Urol. 43:333-337,1971
• Oh W, Kantoff P, Weinberg V et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cáncer. J Clin Oncol. 22(18):3705-3712, 15 Sept 2004
• O´Leary A. Stress, emotion and human immune function? Psychol Bull 108:363,1990
• O´Leary M. Tamsulosin: Current Clinical Experience. Urology 58(suppl 6A): 42-48,2001
• Oldham R. Cáncer biotherapy general principles.In Oldham R edit Principles of cáncer biotherapy ed 2 New York 1991 Dekker M
• Olson K, Pienta K. Vitamins A and E: Further clues for prostate cáncer prevention. J National Cáncer Institute 90:414-415, 1998
• Onozawa M, Kawamori T, Baba M, et al. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn J Cáncer Res 90:393-398, April 1999
• Optenberg S, Thompson I, Friedrichs P, et al. Race, treatment, and long-term survival from prostate cáncer in an equal-access medical care delivery system. JAMA 274(20):1599-1605, 1995.
• Ornish D et al. Can lyfestyle changes reverse prostate cáncer? Journal of Urology 159:218 (abstract 842), 1998
• Ornish D et al. Intensive lyfestyle changes may affect the progression of prostate cáncer. J Urol 174:1065-1070, Sept 2005
• Ouslander J, Greendale G, Uman G et al. Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. J Am Geriatr Soc 49:803-807, 2001
• Pan S, Guh J, Huang Y, et al. Identification of apoptotic and antiangiogenic activities of terazsoin in human prostate cáncer and endothelial cells. Journal of Urology 169(2) 724-729, Feb 2003.
• Parnes H, House M, Kagan J et al. Prostate cáncer chemoprevention agent development: the national cáncer institute, division of cáncer prevention portfolio. J Urol 171(2) part 2 of 2: S68-S75, Feb 2004.
• Patel A, Rodriguez C, Jacobs E et al. Recreational physical activity and risk of prostate cáncer in a large cohort of U.S. men. Cáncer Epidemiol Biomarkers Prev. 14(1):275-279, Jan 2005
• Patterson R et al. Vitamin Supplements and cáncer risk: the epidemiologic evidence. Cáncer Causes and control 8,786-802, 1997
• Pauling L, Rath M. An orthomolecular theory of human health and disease. J Orthomol Med 6:135-138, 1991
• Pareek G, Shevchuk M, Armenakas N et al. The effects of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for drecreased prostatic bleeding in treated patients. J Urol 169 (1) 20-23 Jan 2003
• Pearce N. Traditional epidemiology, modern epidemiology, and public health. Am. J. Public Health 86:678-683, 1996
• Pelucchi C, Talamini R, Galeone C, et al Fibre intake and prostate cáncer risk. Int J Cáncer. 20;109(2):278-280 March 2004
• Pendleton J, Tan W, et al. Treatment of early recurrent (biochemical) prostate cáncer with isoflavonoid. Abstracts #257 J Urol 175(4):85 Suppl May 2006
• Perimenis P, Gyftopoulos K et al. Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasía: a prospective, randomized, controlled study. Urology 59(3):373-377, 2002
• Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cáncer cells but not epidermal growth factor receptor tyrosine autophosphorylation. The Prostate 22(4): 335-345, 1993.